EHA 2023 | Past, present, and future management strategies for non-transfusion dependent β-thalassemia
Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon, delves into the management strategies for non-transfusion dependent beta-thalassemia (NTDT). Prof. Taher emphasizes the importance of targeting ineffective erythropoiesis and iron chelation therapy in this group of patients to decrease morbidity and increase the quality of life (QoL). Prof. Taher also mentions the development of novel therapies including luspatercept, mitapivat, and gene therapies. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultant and research funding: Novartis, Celgene Corp (Bristol Myers Squibb), Vifor Pharma, Pharmacosmos, Agis Pharmaceuticals
